MedDataX Logo

Chemoreflex Sensitivity in Chronic Kidney Disease

NCT ID: NCT00794872

Last Updated: 2008-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 CKD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD \[glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2\], in patients with stage 4 CKD \[GFR 15-29 ml/min/1.73 m2\], as well as in patients without any evidence of CKD. CHRS is measured by determination of the venous partial pressure of oxygen and the heart rate before and after deactivation of the chemoreceptors by inhalation of pure oxygen. The difference in the R-R intervals before and after inhalation divided by the difference in the oxygen pressures is calculated as the CHRS. A CHRS below 3.0 ms/mmHg is defined as pathological. It should be shown that using a simple clinical bedside test we provide the first evidence for impaired hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. We thereby may lay the basis for future intervention studies assessing chemosensor function in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Cardiovascular Morbidity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cardiovascular autonomic neuropathy Chemoreflex sensitivity Chronic kidney disease Sudden cardiac arrest

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with stage 3 CKD

blood sampling

Intervention Type OTHER

2

Patients with stage 4 CKD

blood sampling

Intervention Type OTHER

3

Patients without evidence for CDK

blood sampling

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
* For the reference Patients without evidence for CDK

Exclusion Criteria

* Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heinrich-Heine University, Duesseldorf

OTHER

Sponsor Role collaborator

SLK Kliniken Heilbronn GmbH

OTHER

Sponsor Role collaborator

RWTH Aachen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

RWTH Aachen University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian Meyer, MD

Role: PRINCIPAL_INVESTIGATOR

RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Medicine, Division of Cardiology, Pulmonology and Vascular Medicine

Aachen, North Rhine-Westphalia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Chemoreflex-Sensitivity-Study

Identifier Type: -

Identifier Source: org_study_id